Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Baden-Baden – page 59

1 153 clinical trials in Baden-Baden, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Baden-Baden at a glance
1 153
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 153 trials in Baden-Baden

Open in trial search

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Study on Spironolactone for Patients with Arrhythmogenic Right Ventricular Dysplasia (ARVD)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Hospices Civils De Lyon

Study on Stopping Disease-Modifying Therapies in Inactive Secondary Progressive Multiple Sclerosis Patients Over 50 Using Glatiramer Acetate and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Type 1 diabetes mellitus+2

Not recruiting

Efficacy and Safety of Tirzepatide Versus Placebo in Adults with Type 1 Diabetes and Obesity or Overweight: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

Bronchiectasis

Not recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0292
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Baden-Baden

What the registry says about research in the country

01 Eye Diseases and Ocular Physiology

Clinical research in Baden-Baden includes studies focused on eye diseases and ocular physiological phenomena, with attention on atrophic age-related macular degeneration. These trials are exploring ways to slow disease progression and better understand vision-related decline.

  • Testing a new approach for geographic atrophy linked to AMD
  • Evaluating treatment effectiveness in progressive retinal disease

The goal is to improve care for patients facing gradual loss of vision through more effective targeted therapies.

02 Neoplasms in Breast Cancer Research

A major part of the clinical trial activity in the city centers on breast cancer, including HER2+, HR+/HER2-, and triple-negative early breast cancer. These studies are examining new treatment combinations to strengthen disease control and improve long-term outcomes.

  • Assessing new therapy combinations for HER2+ early breast cancer
  • Comparing treatment strategies in HR+/HER2- early breast cancer
  • Studying options for triple-negative early breast cancer

Research in this area is aimed at improving response rates and reducing the chance of recurrence after initial treatment.

03 Hemic and Lymphatic Diseases

Trials in hematologic malignancies are investigating new strategies for patients with high-risk chronic lymphocytic leukemia. The focus is on whether newer drug combinations can offer stronger disease control than current standard approaches.

  • Evaluating combination treatment for high-risk CLL
  • Studying outcomes in patients with adverse genetic risk factors

These studies are designed to improve progression control and support more personalized treatment choices.

04 Ovarian and Gynecologic Cancer

Another active research area involves advanced ovarian cancer and related gynecologic cancers, including fallopian tube cancer, primary peritoneal cancer, and clear cell carcinoma of the ovary. The trials are examining treatment strategies for patients with no visible residual tumor after surgery.

  • Studying maintenance approaches in HRD-positive high-grade ovarian cancer
  • Evaluating recurrence prevention after primary tumor debulking

These efforts aim to extend recurrence-free survival and refine post-surgical treatment planning.

05 Personalized Oncology in Early Breast Cancer

Several studies are exploring personalized cancer therapy for early-stage breast cancer, using treatment selection to match individual risk profiles. This includes approaches that combine targeted medicine, endocrine therapy, and other systemic treatments.

  • Testing personalized treatment for intermediate- to high-risk HR+/HER2- breast cancer
  • Comparing targeted therapy with standard adjuvant care
  • Improving invasive disease-free survival in early cancer care

In Baden-Baden, this line of research reflects a broader move toward more tailored and effective cancer treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.